Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2007
Quadrivalent human papillomavirus vaccineEliav Barr, Gretchen Tamms
Vaccine|August 13, 2008
Prophylactic HPV vaccines: new interventions for cancer controlEliav Barr, Heather L Sings
The American Journal of Cardiology|January 17, 2002
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone)Alise S Reicin, Deborah Shapiro, Rhoda S Sperling, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
Age-based programs for vaccination against HPVElamin H Elbasha, Erik J Dasbach, Ralph P Insinga, et al.
Wiener Klinische Wochenschrift|January 1, 2009
Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - baseline data of a phase III vaccine trialLucia Six, Sepp Leodolter, Heather L Sings, et al.
Infectious Agents and Cancer|July 14, 2007
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young womenRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 10, 2007
Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectivesRalph P Insinga, Erik J Dasbach, Elamin H Elbasha, et al.
Vaccine|January 1, 2008
Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccinesCosette M Wheeler, Oliver M Bautista, Joanne E Tomassini, et al.
Journal of Viral Hepatitis|November 10, 2018
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysisLawrence Serfaty, Ira Jacobson, Jürgen Rockstroh, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 24, 2017
Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal diseaseK Rajender Reddy, David Roth, Annette Bruchfeld, et al.
Pageof 8